Skip to main content
. 2013 May 9;108(10):2153–2163. doi: 10.1038/bjc.2013.212

Table 2b. Molecular characteristics of colorectal cancer cases in the CRUMS cohort.

  N MSI MSS P-value CIMP-negative CIMP-low CIMP-high P-value
Frequency (%)
414
62 (15.5)
338 (84.5)
 
209 (50.6)
155 (37.5)
49 (11.9)
 
Quadruple Index
 
 
 
<0.0001
 
 
 
<0.0001
Negative 227 (56.0) 19 (31.7) 201 (60.5)   142 (69.3) 82 (54.3) 3 (6.3)  
Positive
178 (44.0)
41 (68.3)
131 (39.5)
 
63 (30.7)
69 (45.7)
45 (93.8)
 
KRAS       0.002       0.001
Wt 331 (80.5) 59 (95.2) 263 (78.3)   174 (83.7) 111 (72.1) 46 (93.9)  
Mutant
80 (19.5)
3 (4.8)
73 (21.7)
 
34 (16.3)
43 (27.9)
3 (6.1)
 
BRAF       <0.0001       <0.0001
Wt 356 (86.8) 27 (44.3) 317 (94.6)   206 (99.0) 143 (92.9) 7 (14.6)  
Mutant
54 (13.2)
34 (55.7)
18 (5.4)
 
2 (1.0)
11 (7.1)
41 (85.4)
 
PIK3CA Exon20
 
 
 
0.013
 
 
 
0.006
Wt 396 (97.8) 55 (93.2) 328 (98.5)   204 (99.0) 150 (98.0) 42 (91.3)  
Mutant
9 (2.2)
4 (6.8)
5 (1.5)
 
2 (1.0)
3 (2.0)
4 (8.7)
 
PTEN
 
 
 
0.719
 
 
 
0.729
Normal 352 (85.9) 52 (83.9) 286 (85.6)   178 (85.6) 134 (87.6) 40 (83.3)  
Loss 58 (14.1) 10 (16.1) 48 (14.4)   30 (14.4) 19 (12.4) 8 (16.7)  

Abbreviations: CIMP=CpG island methylator phenotype; CRUMS=Colorectal Cancer in Umeå Study; MSI=microsatellite instability; MSS=microsatellite stable; Wt=wild-type.

The following numbers of missing cases were present in CRUMS: CIMP status,1; Quadruple Index, 9; KRAS mutation status, 3; BRAF mutation status, 4; PIK3CA mutation status, 9; PTEN mutation status, 4. Cases lacking nuclear staining of tumor cells for at least one of MLH1, MSH2, MSH6 or PMS2 were considered to have a positive MSI screening status (MSI). CIMP according to an eight-gene panel including CDKN2A, hMLH1, CACNA1G, NEUROG1, RUNX3, SOCS1, IGF2 and CRABP1; CIMP-negative, 0 genes hypermethylated; CIMP-low, 1–5 genes hypermethylated; CIMP-high, 6–8 genes hypermethylated. Kruskall–Wallis test was used for continuous variables, χ2-test or Fisher's exact test used for categorical variables.